Daclizumab, a new injectable therapy administered every four weeks, has been approved by Health Canada for the treatment of adult patients with relapsing-remitting MS who have had a poor response or tolerability to at least one prior disease-modifying therapy. The drug received approval on December 8, 2016, and will be marketed as Zinbryta. An intravenous formulation was approved two decades ago (Zenapax) as an anti-rejection drug post-transplant. Zinbryta previously received approval for MS from the U.S. FDA and the European Medicines Agency. Read More
Latest News
NEUROSOUND: CHARCOT 2016 HIGHLIGHTS
January 25, 2017Dr. Daniel Selchen, Director of the Multiple Sclerosis clinic at St. Michael’s Hospital, Toronto, hosts a discussion of highlights from the European Charcot Foundation meeting, held 24-26 November 2016 in Baveno, Italy. Read More
Sun avoidance – more harm than good?
December 16, 2016Two recent papers have recommended that public health recommendations regarding sun avoidance be changed to encourage greater sun exposure. The authors of one paper argue that the health benefits of adequate sun exposure – distinct from vitamin D supplementation – outweigh the risks of skin cancers, and that insufficient sun exposure has become a major public health problem (Hoel et al. Dermatoendocrinol 2016;8:e1248325). Read More
Gum disease linked to cognitive decline in AD
December 7, 2016A six-month observational study has investigated whether periodontitis is associated with dementia severity and cognitive decline in 60 subjects with mild-to-moderate Alzheimer’s disease living in the community (Raybould et al. PLoS One 2016;11:e0151081, free full text at www.ncbi.nlm.nih.gov/pmc/articles/PMC4786266/pdf/pone.0151081.pdfAbstract). Read More